Cutter GR - Search Results

1

Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.

Gaston TE, Ampah SB, Martina Bebin E, Grayson LP, Cutter GR, Hernando K, Szaflarski JP; UAB CBD Program. Gaston TE, et al. Among authors: cutter gr. Epilepsy Behav. 2021 Apr;117:107862. doi: 10.1016/j.yebeh.2021.107862. Epub 2021 Mar 2. Epilepsy Behav. 2021. PMID: 33667843

2

Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill Patients.

Khawaja AM, Wang G, Cutter GR, Szaflarski JP. Khawaja AM, et al. Among authors: cutter gr. Med Sci Monit. 2017 Feb 4;23:649-658. doi: 10.12659/msm.900826. Med Sci Monit. 2017. PMID: 28160596 Free PMC article.

3

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Gaston TE, et al. Among authors: cutter gr. Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6. Epilepsia. 2017. PMID: 28782097

4

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program. Szaflarski JP, et al. Epilepsy Behav. 2018 Oct;87:131-136. doi: 10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9. Epilepsy Behav. 2018. PMID: 30100226 Free article. Clinical Trial.

5

Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.

Martin RC, Gaston TE, Thompson M, Ampah SB, Cutter G, Bebin EM, Szaflarski JP. Martin RC, et al. Epilepsy Behav. 2019 Aug;97:105-110. doi: 10.1016/j.yebeh.2019.04.044. Epub 2019 Jun 18. Epilepsy Behav. 2019. PMID: 31220785

6

Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP; UAB CBD Program. Gaston TE, et al. Among authors: cutter gr. Epilepsy Behav. 2019 Sep;98(Pt A):201-206. doi: 10.1016/j.yebeh.2019.07.008. Epub 2019 Aug 2. Epilepsy Behav. 2019. PMID: 31382177 Clinical Trial.

7

Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy.

Thompson MD, Martin RC, Grayson LP, Ampah SB, Cutter G, Szaflarski JP, Bebin EM. Thompson MD, et al. Epilepsy Behav. 2020 Oct;111:107299. doi: 10.1016/j.yebeh.2020.107299. Epub 2020 Jul 29. Epilepsy Behav. 2020. PMID: 32759071 Clinical Trial.

8

Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy.

Grayson L, Ampah S, Hernando K, Kankirawatana P, Gaston T, Cutter G, Szaflarski JP, Martina Bebin E; UAB CBD Program. Grayson L, et al. Epilepsy Behav. 2021 Sep;122:108190. doi: 10.1016/j.yebeh.2021.108190. Epub 2021 Jul 14. Epilepsy Behav. 2021. PMID: 34273739

9

Efficacy of a premixed semisynthetic human insulin regimen.

Bell DS, Cutter GR, Lauritano AA. Bell DS, et al. Among authors: cutter gr. Clin Ther. 1989 Nov-Dec;11(6):795-801. Clin Ther. 1989. PMID: 2692822

10

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS. Lublin FD, et al. Among authors: cutter gr. Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23. Mult Scler Relat Disord. 2017. PMID: 29141831 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

712 results

Search Page